Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4851
MakeMyTrip
MMYT
$4.2B
| $8.21K | ﹤0.01% |
100
-1,521
| -94% | -$125K |
2025 Q2
2 quarters
|
|
|
APXM
4852
FT Vest U.S. Equity Max Buffer ETF - April
APXM
$20.9M
| $8.2K | ﹤0.01% |
264
+65
| +33% | +$2K |
2025 Q3
1 quarter
|
|
4853
Incannex Healthcare Limited Common Stock
IXHL
$40.3M
| $8.06K | ﹤0.01% |
750
| – | – |
2024 Q1
7 quarters
|
|
4854
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$456M
| $8K | ﹤0.01% |
+203
| New | +$7.94K |
2025 Q4
0 quarters
|
|
|
JBS
4855
JBS N.V.
JBS
$38.4B
| $7.9K | ﹤0.01% |
548
-104,719
| -99% | -$1.44M |
2025 Q3
1 quarter
|
|
|
CHA
4856
Chagee Holdings Ltd
CHA
$2.09B
| $7.9K | ﹤0.01% |
679
-58,426
| -99% | -$868K |
2025 Q3
1 quarter
|
|
4857
TAT Technologies
TATT
$457M
| $7.82K | ﹤0.01% |
175
| – | – |
2025 Q1
3 quarters
|
|
4858
Companhia Siderúrgica Nacional
SID
$1.54B
| $7.71K | ﹤0.01% |
4,817
-225,033
| -98% | -$366K |
2013 Q2
50 quarters
|
|
4859
Codere Online
CDRO
$432M
| $7.7K | ﹤0.01% |
959
| – | – |
2024 Q3
5 quarters
|
|
|
AXIA.PR
4860
DELISTED
AXIA Energia American Depositary Shares Preferred Class B1
AXIA.PR
| $7.49K | ﹤0.01% |
800
-4,010
| -83% | -$36.8K |
2025 Q2
2 quarters
|
|
|
HELP
4861
Helus Pharma Inc. Common Stock
HELP
$855M
| $7.05K | ﹤0.01% |
862
| – | – |
2025 Q2
2 quarters
|
|
4862
Kenon Holdings
KEN
$3.15B
| $6.96K | ﹤0.01% |
105
-753
| -88% | -$42K |
2023 Q2
10 quarters
|
|
|
SIMAU
4863
SIM Acquisition Corp I Unit
SIMAU
| $6.93K | ﹤0.01% |
654
| – | – |
2024 Q4
4 quarters
|
|
4864
NeoVolta
NEOV
$180M
| $6.86K | ﹤0.01% |
+2,257
| New | +$9.53K |
2025 Q4
0 quarters
|
|
4865
Theriva Biologics
TOVX
$10.3M
| $6.85K | ﹤0.01% |
+32,569
| New | +$9.63K |
2025 Q4
0 quarters
|
|
|
FIRY
4866
Firy Inc
FIRY
$207M
| $6.69K | ﹤0.01% |
1,552
-12
| -0.8% | -$74 |
2025 Q3
1 quarter
|
|
4867
UBS Group
UBS
$146B
| $6.53K | ﹤0.01% |
141
-657
| -82% | -$26.5K |
2024 Q4
4 quarters
|
|
4868
Allot
ALLT
$416M
| $6.46K | ﹤0.01% |
657
| – | – |
2025 Q2
2 quarters
|
|
|
MREO
4869
Mereo BioPharma
MREO
$60.7M
| $6.04K | ﹤0.01% |
+14,500
| New | +$27.6K |
2025 Q4
0 quarters
|
|
|
OPENZ
4870
CALL
Opendoor Technologies Inc Series Z Warrants
OPENZ
$2.59M
| $5.99K | ﹤0.01% |
+15,000
| New | +$9.08K |
2025 Q4
0 quarters
|
|
|
BQ
4871
Boqii Holding Ltd
BQ
$5.92M
| $5.94K | ﹤0.01% |
2,925
| – | – |
2023 Q4
8 quarters
|
|
|
DVLT
4872
Datavault AI
DVLT
$146M
| $5.9K | ﹤0.01% |
9,204
-232,426
| -96% | -$407K |
2025 Q3
1 quarter
|
|
|
CMPS
4873
Compass Pathways
CMPS
$1.65B
| $5.88K | ﹤0.01% |
852
-78,915
| -99% | -$481K |
2022 Q1
15 quarters
|
|
|
ASBPW
4874
Aspire-Lakewood Holdings, Inc. Warrant
ASBPW
| $5.78K | ﹤0.01% |
350,000
| – | – |
2022 Q2
14 quarters
|
|
4875
Dermata Therapeutics
DRMA
$5.45M
| $5.57K | ﹤0.01% |
+2,402
| New | +$7.85K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.